Biologics Working Party outlines information for quality portion of investigational applications
This article was originally published in The Gold Sheet
A new guideline from the European Medicines Agency's Biologics Working Party notes that "there are clear differences between the requirements for a dossier for a clinical trial and a marketing authorization dossier. While the latter has to ensure a consistent, state-of-the-art quality of a product for widespread use in patients, information to be provided in an IMP should mainly focus on those quality attributes related to safety aspects." The deadline for public comment is Aug. 31
You may also be interested in...
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.
Head & Shoulders airing a 30-second TV spot featuring Kansas City Chiefs quarterback Patrick Mahomes and former Pittsburgh Steelers safety Troy Polamalu competing over who gives “100%” effort in everything they do.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.